JPWO2020263650A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020263650A5 JPWO2020263650A5 JP2021576604A JP2021576604A JPWO2020263650A5 JP WO2020263650 A5 JPWO2020263650 A5 JP WO2020263650A5 JP 2021576604 A JP2021576604 A JP 2021576604A JP 2021576604 A JP2021576604 A JP 2021576604A JP WO2020263650 A5 JPWO2020263650 A5 JP WO2020263650A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- macrophages
- agent
- bone marrow
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002798 bone marrow cell Anatomy 0.000 claims 76
- 210000004027 cell Anatomy 0.000 claims 75
- 239000003795 chemical substances by application Substances 0.000 claims 75
- 206010028980 Neoplasm Diseases 0.000 claims 58
- 230000000694 effects Effects 0.000 claims 53
- 210000002540 macrophage Anatomy 0.000 claims 50
- 238000000034 method Methods 0.000 claims 44
- 201000011510 cancer Diseases 0.000 claims 43
- 210000000066 myeloid cell Anatomy 0.000 claims 38
- 239000000427 antigen Substances 0.000 claims 35
- 102000036639 antigens Human genes 0.000 claims 35
- 108091007433 antigens Proteins 0.000 claims 35
- 239000012634 fragment Substances 0.000 claims 30
- 230000002757 inflammatory effect Effects 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 101001039157 Homo sapiens Leucine-rich repeat-containing protein 25 Proteins 0.000 claims 22
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 20
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 20
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102100040695 Leucine-rich repeat-containing protein 25 Human genes 0.000 claims 18
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims 18
- 210000004322 M2 macrophage Anatomy 0.000 claims 17
- 210000004443 dendritic cell Anatomy 0.000 claims 17
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 16
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 16
- 102100022338 Integrin alpha-M Human genes 0.000 claims 16
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 16
- 210000003690 classically activated macrophage Anatomy 0.000 claims 16
- 210000000440 neutrophil Anatomy 0.000 claims 16
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 15
- 230000028327 secretion Effects 0.000 claims 13
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 12
- 210000001616 monocyte Anatomy 0.000 claims 12
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 11
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 11
- 238000002560 therapeutic procedure Methods 0.000 claims 11
- 108090001005 Interleukin-6 Proteins 0.000 claims 10
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 9
- 239000002955 immunomodulating agent Substances 0.000 claims 9
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 8
- 238000001727 in vivo Methods 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 230000001105 regulatory effect Effects 0.000 claims 8
- 210000001519 tissue Anatomy 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 7
- 230000006044 T cell activation Effects 0.000 claims 7
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 7
- 102000018358 immunoglobulin Human genes 0.000 claims 7
- 210000000822 natural killer cell Anatomy 0.000 claims 7
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 230000007115 recruitment Effects 0.000 claims 6
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims 5
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 5
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 5
- 108010009992 CD163 antigen Proteins 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 5
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 5
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 claims 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 5
- 101000576894 Homo sapiens Macrophage mannose receptor 1 Proteins 0.000 claims 5
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 5
- 101000743488 Homo sapiens V-set and immunoglobulin domain-containing protein 4 Proteins 0.000 claims 5
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 5
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 5
- 102000013462 Interleukin-12 Human genes 0.000 claims 5
- 108010065805 Interleukin-12 Proteins 0.000 claims 5
- 102000003810 Interleukin-18 Human genes 0.000 claims 5
- 108090000171 Interleukin-18 Proteins 0.000 claims 5
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 claims 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 5
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 claims 5
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 5
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 claims 5
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 claims 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 5
- 102100038296 V-set and immunoglobulin domain-containing protein 4 Human genes 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 5
- 238000003556 assay Methods 0.000 claims 5
- 229940022399 cancer vaccine Drugs 0.000 claims 5
- 238000009566 cancer vaccine Methods 0.000 claims 5
- 210000001787 dendrite Anatomy 0.000 claims 5
- 230000002601 intratumoral effect Effects 0.000 claims 5
- 230000002147 killing effect Effects 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 238000000386 microscopy Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000004044 response Effects 0.000 claims 5
- 230000004936 stimulating effect Effects 0.000 claims 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 4
- 238000010171 animal model Methods 0.000 claims 4
- 102000048581 human LRRC25 Human genes 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 238000011275 oncology therapy Methods 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 102000019034 Chemokines Human genes 0.000 claims 3
- 108010012236 Chemokines Proteins 0.000 claims 3
- 238000002965 ELISA Methods 0.000 claims 3
- 241000282567 Macaca fascicularis Species 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- -1 TGFb Proteins 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 230000009467 reduction Effects 0.000 claims 3
- 230000002829 reductive effect Effects 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 238000002626 targeted therapy Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 238000011374 additional therapy Methods 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 230000008901 benefit Effects 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 208000024312 invasive carcinoma Diseases 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 238000003127 radioimmunoassay Methods 0.000 claims 2
- 230000001235 sensitizing effect Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032320 Germ cell tumor of testis Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 238000012575 bio-layer interferometry Methods 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 201000003914 endometrial carcinoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000030173 low grade glioma Diseases 0.000 claims 1
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 230000036961 partial effect Effects 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 208000002918 testicular germ cell tumor Diseases 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 210000003741 urothelium Anatomy 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867593P | 2019-06-27 | 2019-06-27 | |
| US62/867,593 | 2019-06-27 | ||
| PCT/US2020/038115 WO2020263650A1 (en) | 2019-06-27 | 2020-06-17 | Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022539038A JP2022539038A (ja) | 2022-09-07 |
| JPWO2020263650A5 true JPWO2020263650A5 (https=) | 2023-06-26 |
| JP2022539038A5 JP2022539038A5 (https=) | 2023-06-26 |
Family
ID=74060354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576604A Pending JP2022539038A (ja) | 2019-06-27 | 2020-06-17 | 骨髄細胞炎症性表現型を調節するための抗ｌｒｒｃ２５組成物及び方法、ならびにその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220363752A1 (https=) |
| EP (1) | EP3990017A4 (https=) |
| JP (1) | JP2022539038A (https=) |
| KR (1) | KR20220042131A (https=) |
| CN (1) | CN114423452A (https=) |
| AU (1) | AU2020306772A1 (https=) |
| BR (1) | BR112021026411A2 (https=) |
| CA (1) | CA3142838A1 (https=) |
| IL (1) | IL289166A (https=) |
| WO (1) | WO2020263650A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3267340A1 (en) * | 2022-10-05 | 2024-04-11 | Shangpharma Innovation, Inc. | Anti-urokinase type plasminogen activator receptor antibodies and methods of use |
| CN116380755B (zh) * | 2023-03-20 | 2023-11-21 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101122628B1 (ko) * | 2009-02-16 | 2012-04-12 | 한국화학연구원 | 노닐페놀에 의해 유도된 생식독성 진단용 바이오마커 및 이를 이용한 생식독성 진단 방법 |
| US10279018B2 (en) * | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
| WO2016203053A2 (en) * | 2015-06-18 | 2016-12-22 | Thomas Mole Herd | Methods of characterising cancer |
| WO2017004153A1 (en) * | 2015-06-29 | 2017-01-05 | The Broad Institute Inc. | Tumor and microenvironment gene expression, compositions of matter and methods of use thereof |
| JP7078533B2 (ja) * | 2015-10-21 | 2022-05-31 | オーエスイー イムノセラピューティクス | 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物 |
| CN109313201B (zh) * | 2016-06-14 | 2022-04-01 | 高级生物设计公司 | 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体 |
| US20190233534A1 (en) * | 2016-07-14 | 2019-08-01 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| JP2021529753A (ja) * | 2018-06-29 | 2021-11-04 | ヴェルソー セラピューティクス， インコーポレイテッド | 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法 |
-
2020
- 2020-06-17 CA CA3142838A patent/CA3142838A1/en active Pending
- 2020-06-17 EP EP20833200.7A patent/EP3990017A4/en not_active Withdrawn
- 2020-06-17 CN CN202080061285.3A patent/CN114423452A/zh active Pending
- 2020-06-17 KR KR1020227003081A patent/KR20220042131A/ko not_active Ceased
- 2020-06-17 WO PCT/US2020/038115 patent/WO2020263650A1/en not_active Ceased
- 2020-06-17 BR BR112021026411A patent/BR112021026411A2/pt not_active IP Right Cessation
- 2020-06-17 US US17/620,264 patent/US20220363752A1/en not_active Abandoned
- 2020-06-17 AU AU2020306772A patent/AU2020306772A1/en not_active Abandoned
- 2020-06-17 JP JP2021576604A patent/JP2022539038A/ja active Pending
-
2021
- 2021-12-20 IL IL289166A patent/IL289166A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529753A5 (https=) | ||
| KR20180011250A (ko) | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 | |
| US20220169694A1 (en) | Chimeric antigen receptor t cell therapy | |
| KR20180011251A (ko) | T 세포 요법을 위한 진단 방법 | |
| WO2013012414A1 (en) | Dosing regimens for treatment of cea-expressing cancers | |
| JP2022527941A (ja) | 光免疫療法のための方法および関連バイオマーカー | |
| CN112703012A (zh) | 治疗癌症的方法 | |
| JP6944925B2 (ja) | 組織浸潤ｎｋ細胞を検出する方法 | |
| JPWO2020006385A5 (https=) | ||
| JP2022511337A (ja) | 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 | |
| US11648307B2 (en) | Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy | |
| US20250313855A1 (en) | Chimeric antigen receptor t cell therapy | |
| JP2021500336A (ja) | 抗ｃｄ４７及び抗ｐｄ−ｌ１による卵巣癌の処置 | |
| Schepisi et al. | Urothelial cancer: inflammatory mediators and implications for immunotherapy | |
| Cole et al. | First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors | |
| WO2021245249A1 (en) | Treatment of cd30-positive cancer | |
| JPWO2020247371A5 (https=) | ||
| JPWO2020247372A5 (https=) | ||
| JPWO2021243169A5 (https=) | ||
| JPWO2020263650A5 (https=) | ||
| JPWO2020263651A5 (https=) | ||
| EP3388073A1 (en) | Targeting mesothelin in brain cancer | |
| EP4384276A1 (en) | Biomarkers for cd40 agonist therapy | |
| CN117795341A (zh) | 使用cd-40激动剂治疗癌症的方法 | |
| CN116322753A (zh) | 用于胰腺癌评价和治疗的方法和组合物 |